Nctid:
NCT00001169
Payload:
{"hasResults"=>false, "derivedSection"=>{"miscInfoModule"=>{"versionHolder"=>"2024-12-06"}, "conditionBrowseModule"=>{"meshes"=>[{"id"=>"D007896", "term"=>"Leishmaniasis"}, {"id"=>"D007898", "term"=>"Leishmaniasis, Visceral"}], "ancestors"=>[{"id"=>"D007239", "term"=>"Infections"}, {"id"=>"D056986", "term"=>"Euglenozoa Infections"}, {"id"=>"D011528", "term"=>"Protozoan Infections"}, {"id"=>"D010272", "term"=>"Parasitic Diseases"}, {"id"=>"D012876", "term"=>"Skin Diseases, Parasitic"}, {"id"=>"D000079426", "term"=>"Vector Borne Diseases"}, {"id"=>"D012874", "term"=>"Skin Diseases, Infectious"}, {"id"=>"D012871", "term"=>"Skin Diseases"}], "browseLeaves"=>[{"id"=>"M10283", "name"=>"Infections", "relevance"=>"LOW"}, {"id"=>"M6368", "name"=>"Communicable Diseases", "relevance"=>"LOW"}, {"id"=>"M10908", "name"=>"Leishmaniasis", "asFound"=>"Leishmaniasis", "relevance"=>"HIGH"}, {"id"=>"M10910", "name"=>"Leishmaniasis, Visceral", "asFound"=>"Leishmaniasis, Visceral", "relevance"=>"HIGH"}, {"id"=>"M28673", "name"=>"Euglenozoa Infections", "relevance"=>"LOW"}, {"id"=>"M14388", "name"=>"Protozoan Infections", "relevance"=>"LOW"}, {"id"=>"M13185", "name"=>"Parasitic Diseases", "relevance"=>"LOW"}, {"id"=>"M15674", "name"=>"Skin Diseases", "relevance"=>"LOW"}, {"id"=>"M15679", "name"=>"Skin Diseases, Parasitic", "relevance"=>"LOW"}, {"id"=>"M2054", "name"=>"Vector Borne Diseases", "relevance"=>"LOW"}, {"id"=>"M15677", "name"=>"Skin Diseases, Infectious", "relevance"=>"LOW"}, {"id"=>"T3368", "name"=>"Leishmaniasis", "asFound"=>"Leishmaniasis", "relevance"=>"HIGH"}], "browseBranches"=>[{"name"=>"Infections", "abbrev"=>"BC01"}, {"name"=>"All Conditions", "abbrev"=>"All"}, {"name"=>"Symptoms and General Pathology", "abbrev"=>"BC23"}, {"name"=>"Skin and Connective Tissue Diseases", "abbrev"=>"BC17"}, {"name"=>"Rare Diseases", "abbrev"=>"Rare"}]}}, "protocolSection"=>{"designModule"=>{"studyType"=>"OBSERVATIONAL", "enrollmentInfo"=>{"count"=>250}}, "statusModule"=>{"overallStatus"=>"COMPLETED", "startDateStruct"=>{"date"=>"1979-12"}, "expandedAccessInfo"=>{"hasExpandedAccess"=>false}, "statusVerifiedDate"=>"2000-02", "completionDateStruct"=>{"date"=>"2001-02"}, "lastUpdateSubmitDate"=>"2008-03-03", "studyFirstSubmitDate"=>"1999-11-03", "studyFirstSubmitQcDate"=>"2002-12-09", "lastUpdatePostDateStruct"=>{"date"=>"2008-03-04", "type"=>"ESTIMATED"}, "studyFirstPostDateStruct"=>{"date"=>"2002-12-10", "type"=>"ESTIMATED"}}, "conditionsModule"=>{"keywords"=>["Chemotherapy", "Cytokines", "Immunology", "Kala-Azar", "Leishmaniasis"], "conditions"=>["Leishmaniasis", "Leishmaniasis, Visceral"]}, "referencesModule"=>{"references"=>[{"pmid"=>"1670724", "type"=>"BACKGROUND", "citation"=>"Ponce C, Ponce E, Morrison A, Cruz A, Kreutzer R, McMahon-Pratt D, Neva F. Leishmania donovani chagasi: new clinical variant of cutaneous leishmaniasis in Honduras. Lancet. 1991 Jan 12;337(8733):67-70. doi: 10.1016/0140-6736(91)90734-7."}, {"pmid"=>"2802018", "type"=>"BACKGROUND", "citation"=>"Velasco O, Savarino SJ, Walton BC, Gam AA, Neva FA. Diffuse cutaneous leishmaniasis in Mexico. Am J Trop Med Hyg. 1989 Sep;41(3):280-8."}, {"pmid"=>"2104665", "type"=>"BACKGROUND", "citation"=>"Badaro R, Falcoff E, Badaro FS, Carvalho EM, Pedral-Sampaio D, Barral A, Carvalho JS, Barral-Netto M, Brandely M, Silva L, et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med. 1990 Jan 4;322(1):16-21. doi: 10.1056/NEJM199001043220104."}]}, "descriptionModule"=>{"briefSummary"=>"Mechanisms of host immune response to intracellular protozoa will be investigated in patients with naturally acquired infection employing a variety of in-vitro techniques. Both non-specific and antigen-specific humoral and cellular immune responses will be assessed. Parasites will be isolated from patients, cultivated in-vitro, and characterized. Responses to chemotherapy will be assessed parasitologically, immunologically and clinically.", "detailedDescription"=>"The main purpose of this protocol is to permit us to see patients who are referred to us for diagnosis and treatment of known or suspected leishmaniasis (from the Peace Corps, Smithsonian Institution, tourists, etc.). In the process of working up these patients, we sometimes encounter parasite isolates that are useful for research. We also can perform tests of cell-mediated immune function to evaluate how patients are responding to therapy. In addition, the protocol permits us to observe therapeutic responses to other drugs besides pentavalent antimony, if necessary."}, "eligibilityModule"=>{"sex"=>"ALL", "stdAges"=>["CHILD", "ADULT", "OLDER_ADULT"], "healthyVolunteers"=>true, "eligibilityCriteria"=>"Must be between the ages of 1 and 65 years."}, "identificationModule"=>{"nctId"=>"NCT00001169", "briefTitle"=>"Clinical Investigation of Infections Due to Leishmanial Parasites", "organization"=>{"class"=>"NIH", "fullName"=>"National Institutes of Health Clinical Center (CC)"}, "officialTitle"=>"Clinical Investigation of Infections Due to Leishmanial Parasites", "orgStudyIdInfo"=>{"id"=>"790144"}, "secondaryIdInfos"=>[{"id"=>"79-I-0144"}]}, "contactsLocationsModule"=>{"locations"=>[{"zip"=>"20892", "city"=>"Bethesda", "state"=>"Maryland", "country"=>"United States", "facility"=>"National Institute of Allergy and Infectious Diseases (NIAID)", "geoPoint"=>{"lat"=>38.98067, "lon"=>-77.10026}}]}, "sponsorCollaboratorsModule"=>{"leadSponsor"=>{"name"=>"National Institute of Allergy and Infectious Diseases (NIAID)", "class"=>"NIH"}}}}
